• PDF / 169,781 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 25 Downloads / 201 Views

DOWNLOAD

REPORT

503/20/0867-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 28 Nov 2020 No. 867

1

Recommend Documents

Applicability of radiomics in interstitial lung disease associated with systemic sclerosis: proof of concept

137 83 2MB

Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease:

206 98 488KB

Mycophenolate Mofetil Improves Exercise Tolerance in Systemic Sclerosis Patients with Interstitial Lung Disease: A Pilot

166 57 422KB

Challenges in physician-patient communication for optimal management of systemic sclerosis-associated interstitial lung

133 47 684KB

Interstitial lung disease in patients with scleroderma - Treatment with rituximab

162 66 120KB

Pulmonary Hypertension and Interstitial Lung Disease

155 69 7MB

Interstitial lung disease risk with prostate cancer meds

158 99 148KB

Leflunomide may be associated with an increased risk of interstitial lung disease (ILD) in Korean patients

189 81 133KB

Lung Cancer Complicated with Interstitial Lung Diseases

161 12 9MB

Comparison of Clinical Measures Among Interstitial Lung Disease (ILD) Patients with Usual Interstitial Pneumonia (UIP) P

150 39 790KB

Systemic Sclerosis

156 70 57MB

Systemic Sclerosis

156 3 11MB